MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Country |
 USA |
IPO year |
2011 |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
25.8 M |
Market Cap[1] |
$ 6.35 M |
EBITDA (LTM) |
$ -27.6 M |
P/E (LTM) |
- |
P/S (LTM) |
15.96 |
EPS (LTM) |
-0.44 |
Other stocks of industry "Drug manufacturers"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | USA |
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | USA |
 |
Canopy Growth Corporation
CGC
|
$ 1.14 | - | $ 123 M | Nasdaq Global Select Market |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | USA |
 |
Cronos Group
CRON
|
$ 2.63 | - | $ 1.38 B | Nasdaq Global Market | Canada |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | USA |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB |  Irlanda |
 |
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | USA |
 |
Aurora Cannabis
ACB
|
$ 4.22 | - | $ 86.3 M | NYSE | Canada |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market |  Schweden |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | Canada |
 |
Emergent BioSolutions
EBS
|
$ 12.36 | - | $ 633 M | NYSE,SPB | USA |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
$ 21.55 | - | $ 2.05 B | Nasdaq Global Select Market |  France |
 |
Evolus
EOLS
|
$ 6.65 | - | $ 412 M | Nasdaq Global Market | USA |
 |
Harrow Health
HROW
|
$ 49.0 | - | $ 1.6 B | Nasdaq Global Market | USA |
 |
China Pharma Holdings
CPHI
|
$ 1.21 | - | $ 21.1 M | NYSE American |  China |
 |
Organogenesis Holdings
ORGO
|
$ 5.18 | - | $ 682 M | Nasdaq Capital Market | USA |
 |
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | Canada |
 |
Pacira BioSciences
PCRX
|
$ 25.88 | - | $ 1.2 B | Nasdaq Global Select Market,SPB | USA |
 |
OrganiGram Holdings
OGI
|
$ 1.68 | - | $ 402 M | Nasdaq Global Select Market | Canada |
 |
Bausch Health Companies
BHC
|
$ 6.95 | - | $ 2.54 B | NYSE | Canada |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | USA |
 |
Sundial Growers
SNDL
|
$ 1.66 | - | $ 3.37 M | Nasdaq Global Select Market | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
$ 3.64 | - | $ 4.52 M | Nasdaq Capital Market | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
$ 3.98 | - | $ 56 M | Nasdaq Global Select Market | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | USA |
 |
Rockwell Medical
RMTI
|
$ 0.83 | - | $ 19.4 M | Nasdaq Global Market | USA |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | USA |
 |
Veru
VERU
|
$ 2.14 | - | $ 289 M | Nasdaq Capital Market | USA |
 |
Perrigo Company plc
PRGO
|
$ 13.92 | - | $ 1.91 B | NYSE | USA |
 |
ProPhase Labs
PRPH
|
$ 0.45 | - | $ 7.13 M | Nasdaq Capital Market | USA |
 |
cbdMD
YCBD
|
$ 1.35 | - | $ 5.82 M | NYSE American | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | USA |
 |
Relmada Therapeutics
RLMD
|
$ 4.83 | - | $ 145 M | Nasdaq Global Select Market,SPB | USA |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | USA |
 |
Assertio Holdings
ASRT
|
$ 9.07 | -1.41 % | $ 644 M | Nasdaq Capital Market | USA |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | USA |
 |
Solid Biosciences
SLDB
|
$ 5.64 | - | $ 230 M | Nasdaq Global Select Market,SPB | USA |
 |
SCYNEXIS
SCYX
|
$ 0.63 | - | $ 30.1 M | Nasdaq Global Select Market | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | USA |
 |
Tilray
TLRY
|
$ 9.03 | - | $ 5.58 B | Nasdaq Global Select Market | Canada |
 |
TherapeuticsMD
TXMD
|
$ 1.63 | - | $ 17 M | Nasdaq Global Select Market | USA |
 |
Viatris
VTRS
|
$ 12.45 | - | $ 15.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.